TAKEDA PHARMACEUTICAL COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.02 USD | -0.31% |
|
-2.18% | -8.76% |
| 16/05 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
| 15/05 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
| Sales 2024 | 4,26400Cr 2.71TCr 2,25800Cr | Sales 2025 * | 4,10800Cr 2.62TCr 2,17500Cr | Capitalization | 6,48600Cr 4.13TCr 3,43500Cr |
|---|---|---|---|---|---|
| Net income 2024 | 14TCr 92Cr 7.63TCr | Net income 2025 * | 14TCr 86Cr 7.19TCr | EV / Sales 2024 | 1.54 x |
| Net Debt 2024 * | 3,77100Cr 2.4TCr 1,99700Cr | Net Debt 2025 * | 4,20400Cr 2.68TCr 2,22600Cr | EV / Sales 2025 * | 2.6 x |
| P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
45.8
x | Employees | 49,095 |
| Yield 2024 * |
4.55% | Yield 2025 * |
4.61% | Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Takeda Pharmaceutical Company Limited
More recommendations
More press releases
More news
| 1 day | -0.31% | ||
| 1 week | -2.18% | ||
| Current month | -0.46% | ||
| 1 month | -2.69% | ||
| 3 months | -10.94% | ||
| 6 months | -7.00% | ||
| Current year | -8.76% |
1 week
12.99
13.33
1 month
12.7713.49
Current year
12.7715.07
1 year
12.7716.39
3 years
12.2817.43
5 years
12.2820.93
10 years
12.2831.29
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 01/14/01 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 01/22/01 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 01/12/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 01/16/01 | |
Ian Clark
BRD | Director/Board Member | 62 | 01/19/01 |
Steven Gillis
BRD | Director/Board Member | 71 | 01/19/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.42% | 9 M€ | -4.31% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/24/23 | 13.02 | -0.31% | 1,351,199 |
| 22/24/22 | 13.06 | -1.06% | 1,034,010 |
| 21/24/21 | 13.2 | -0.60% | 1,014,579 |
| 20/24/20 | 13.28 | +0.45% | 594,402 |
| 17/24/17 | 13.22 | -0.68% | 1,009,727 |
Delayed Quote Nyse, May 24, 2024 at 01:30 am IST
More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
04/06/2024
- Sleep Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,134
JPY
Average target price
4,762
JPY
Spread / Average Target
+15.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.69% | 72TCr | |
| +34.28% | 59TCr | |
| -4.49% | 37TCr | |
| +20.24% | 33TCr | |
| +2.12% | 28TCr | |
| +17.02% | 24TCr | |
| +9.31% | 21TCr | |
| -5.07% | 21TCr | |
| -0.35% | 17TCr |
- Stock Market
- Equities
- 4502 Stock
- TAK Stock
